370 AJM300, an Oral α4 Integrin Antagonist, for Active Ulcerative Colitis: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2A Study

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Gastroenterology

• Publication date

  2014-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S0016-5085(14)60293-6
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• No references are available for this paper.

• Placebo response and remission rates in randomised trials of induction and maintenance therapy for ulcerative colitis.

  2017cites this paper
• Breast cancer metastasis: Putative therapeutic role of vascular cell adhesion molecule-1

  2017cites this paper
• Novel Therapies in Inflammatory Bowel Disease: An Evaluation of the Evidence

  2016cites this paper
• Immune Based Therapies for Inflammatory Bowel Disease

  2016cites this paper
• Medical Therapy: The Future

  2015cites this paper
• New targeted therapies such as anti-adhesion molecules, anti-IL-12/23 and anti-Janus kinases are looking toward a more effective treatment of inflammatory bowel disease

  2015cites this paper
• Targeting vascular and leukocyte communication in angiogenesis, inflammation and fibrosis

  2015cites this paper
• The unusual suspects—innate lymphoid cells as novel therapeutic targets in IBD

  2015cites this paper
• Current stage in inflammatory bowel disease: What is next?

  2015cites this paper
• Lymphocyte homing antagonists in the treatment of inflammatory bowel diseases.

  2014cites this paper